Upcoming Conferences in the Life Sciences Industry

The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022, the conference demonstrated the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1,100 participants across the globe. In 2023, the Swiss Biotech Day will again offer high-level experts from the life science industry the space to network, discuss and discover trends in R&D, manufacturing, data management, artificial intelligence and innovative financing over one and a half days. In addition, international biotech delegations can take part in the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments, public-private partnerships, research and development collaborations and exchange of talent.

Our inaugural event convenes industry stakeholders to accelerate access to transformative cell and gene products. Under the stewardship of The Economist editors, our inaugural event on cell and gene therapies convenes industry stakeholders to accelerate access to transformative products. Cell and gene therapies are redefining the treatment of many diseases, giving hope to patients who previously had no therapeutic options. These treatments can be transformative in the battle against cancer, genetic disorders and rare diseases. In the UK, NICE expects to review 30 new cell and gene therapy products by 2023, with the FDA in the US predicting between 15 and 20 new products will be on the market by 2025. Attendees will learn how healthcare systems and policies need to evolve before these therapies can become mainstream. Through a series of interactive sessions, industry stakeholders will debate the challenges of bringing these therapies to market—including manufacturing, real-world data collection and their commercial sustainability. Our conference programme examines the potential for a healthcare paradigm shift, as public opinion and patient experience evolve. We will also assess the innovations needed in pricing policies and payments to combat “big sticker” price tags—some products are $2.48 million per dose—and how they limit accessibility.

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions. Interacting with new companies each year is something we believe to be a critical attribute of a successful conference and we work hard to ensure that a substantial and fresh line-up of investable opportunities and collaboration possibilities are showcased.

Building on the success of its sister event—ChinaBio® Partnering Forum—Asia Bio Partnering Forum will bring together hundreds of innovators from key Asian markets with life science leaders from around the world to advance dealmaking across Asia.

Biotechgate Digital Partnering is a virtual conference designed to support the business development of Biotech, Medtech and Pharma companies. Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings, along with informal networking events and workshops.

Keynotion Global Bioprocessing Summit brings together leading bioprocessing scientists and engineers to share day-to-day challenges and practical solutions for the development, manufacturing and quality of antibodies, vaccines and gene therapies. This world class conference is a mixture of Comprehensive Workshop, detailed case studies and interactive discussions in cell culture, scale-up, continuous Biomanufacturing, recovery, purification, process and product characterization, and formulation.

The investor day will again bring an international flavor. Nordic and Norwegian life science investors focusing on health, bioindustrials, sustainability and life science based solutions, will meet and partner 1:1 with life science companies and other investors. Last year’s conference brought ca 120 participants and 50+ 1:1 meetings between investors and companies. Sustainable solutions across industries will require looking at problems and needs from different perspectives. Precision, digitalization, documentation and sustainability will be important as new solutions are developed. The greatest shifts are always the greatest innovation drivers. Learn how Norwegian and Nordic investors make focus on sustainable solutions a competitive advantage.

he Product & Company Valuation course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic development decisions in the pharma-biotech world. This introductory course is very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors which shape the risk profile of the company in question. This course optimally balances interactive lectures with practical group work exercises that are designed to help you practice the fundamental valuation tools & techniques taught throughout the day. Valuation is an inherently subjective task, which is made even more difficult in the life science industry due to its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies, IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the “Product Valuation and Deal Structuring” module where registrants will learn the commonly used rNPV (i.e., risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. Registrants will use an Excel-based tool designed specifically for this module, which can be taken home for future use.

The Biotech CEO Summits are unlike most meetings CEOs attend. It is not an investor conference nor is it a business development conference. Rather, the Summits’ focus is on the CEOs and the challenges they have leading their companies. The program is modeled after a think tank-style meeting with discussions led by subject matter experts with input from the CEOs. The CEOs benefit from the wisdom and experiences shared by other participating CEOs and the discussants. The Summits operate under Chatham House Rules to encourage open and frank conversations. The number of participants is limited to allow full engagement. Registration is not open; one has to be asked to join this event. The Summits are closed to media and the sessions are not recorded in order to provide an extra layer of privacy.

IO Asia–Taiwan 2023 Onsite + Online will be held July 26-30, in Taipei, Taiwan. The event aims to build on the success of recent years’ gatherings to bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia, and explore business opportunities and to engage with Taiwan’s emerging biotech sector. The five-day gathering will feature a three-day conference with internationally-renowned speakers, company presentations from Asia and around the world, BIO One-on-One Partnering™ meetings, symposia and workshops, and an international exhibition. Each element of the gathering will also be accessible online in either live or on-demand formats; ideal for repeat viewings or for delegates unable to attend in person. Online participation in 2022 was impressive, with 13,000 online conference and 215,000 online exhibition views. This year’s theme, Embracing Asian Dynamics, showcases the incredible opportunities that exist within Asian’s fast moving economies, its dynamic and innovation-generating biomedical ecosystems, and its globally-connected bio-industry production and value chains. Featuring the latest advances from the therapeutic, diagnostic, medical equipment, and service sectors, BIO Asia–Taiwan 2023 Onsite + Online is notably hosted in Taiwan, recognized worldwide not only for its efforts in successfully fighting the spread of COVID-19, but also in cultivating a high level of innovation and production, leading to increasing engagement with the international biomedical community. The event promises attendees a wide range of seminars and panel discussions on industry-critical, cutting-edge topics from 100+ renowned speakers, while providing networking with a wide range of high-quality companies and solution providers.

An Introductory Course Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world – Know how to assess and calculate the value of a biotech company – Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal.

An Introductory Course: Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world – Know how to assess and calculate the value of a biotech company – Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal.